PMID- 28083606
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20231213
IS  - 1661-4917 (Electronic)
IS  - 0004-069X (Linking)
VI  - 64
IP  - Suppl 1
DP  - 2016 Dec
TI  - The Influence of HLA and KIR Genes on Malignant Melanoma Development and 
      Progression.
PG  - 73-81
LID - 10.1007/s00005-016-0437-3 [doi]
AB  - Many studies have described the role of killer immunoglobulin-like receptors 
      (KIRs) and their cognate human leukocyte antigen (HLA) class I ligands in the 
      immune protection against melanoma, but the effect of these markers on 
      intra-individual variations in tumor development and progression has remained 
      less clear. We performed KIR, HLA, and KIR/ligand analysis in 283 patients with 
      malignant melanoma in order to evaluate their integrated influence on disease 
      stage and progression. The patients were grouped according to AJCC staging, 
      histological type of the primary tumor, progression, and survival rate. Analysis 
      of HLA class I alleles revealed positive association of HLA-C*14 (Pc = 0.026, 
      OR = 5.99) and negative association of HLA-C*02 (Pc = 0.026, OR = 0.43) with the 
      disease. Decreased frequency of KIR2DS5 was observed in patients with rapid 
      progression, as compared to those with slow progression. KIR BB genotype was 
      prevalent in patients with metastasis (p = 0.004, OR = 0.025). KIR AA genotype 
      was nearly twice as frequent in rapidly progressive cases, but without 
      statistical relevance (p = 0.055, OR = 2.6). Significantly increased frequency of 
      KIR2DL2 in the presence of C1 ligand (strong inhibition) was found in patients 
      with AJCC III and IV, as compared to individuals with AJCC I stage (p = 0.045, 
      OR = 1.93). In summary, our data imply that KIR/ligand gene content in patients 
      could modulate the disease course towards unfavorable tumor behavior.
FAU - Kandilarova, Snezhina Mihailova
AU  - Kandilarova SM
AD  - Department of Clinical Immunology with Stem Cell Bank, Alexandrovska University 
      Hospital, Medical University, 1431, Sofia, Bulgaria. sneji_jm@yahoo.com.
FAU - Paschen, Annette
AU  - Paschen A
AD  - Department of Dermatology, University Hospital Essen, Essen, Germany.
FAU - Mihaylova, Anastassia
AU  - Mihaylova A
AD  - Department of Clinical Immunology with Stem Cell Bank, Alexandrovska University 
      Hospital, Medical University, 1431, Sofia, Bulgaria.
FAU - Ivanova, Milena
AU  - Ivanova M
AD  - Department of Clinical Immunology with Stem Cell Bank, Alexandrovska University 
      Hospital, Medical University, 1431, Sofia, Bulgaria.
FAU - Schadendorf, Dirk
AU  - Schadendorf D
AD  - Department of Dermatology, University Hospital Essen, Essen, Germany.
FAU - Naumova, Elissaveta
AU  - Naumova E
AD  - Department of Clinical Immunology with Stem Cell Bank, Alexandrovska University 
      Hospital, Medical University, 1431, Sofia, Bulgaria.
LA  - eng
PT  - Journal Article
DEP - 20170112
PL  - Poland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A3 Antigen)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Amino Acid Motifs
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - HLA-A3 Antigen/genetics
MH  - HLA-C Antigens/genetics
MH  - Histocompatibility Antigens Class I/genetics
MH  - Humans
MH  - Killer Cells, Natural/cytology
MH  - Ligands
MH  - Male
MH  - Melanoma/*genetics/immunology
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Receptors, KIR/*genetics
MH  - Receptors, KIR2DL3/genetics
MH  - Skin Neoplasms/genetics/immunology
MH  - Treatment Outcome
MH  - Melanoma, Cutaneous Malignant
OTO - NOTNLM
OT  - Human leukocyte antigens (HLA)
OT  - Inhibitory killer immunoglobulin-like receptors (KIR)
OT  - Malignant melanoma
OT  - Progression
EDAT- 2017/01/14 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/01/14 06:00
PHST- 2016/06/13 00:00 [received]
PHST- 2016/10/25 00:00 [accepted]
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
PHST- 2017/01/14 06:00 [entrez]
AID - 10.1007/s00005-016-0437-3 [pii]
AID - 10.1007/s00005-016-0437-3 [doi]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):73-81. doi: 
      10.1007/s00005-016-0437-3. Epub 2017 Jan 12.